SelectImmune Pharma announces new patent granted for IRF7 inhibitors case
SelectImmune Pharma AB is pleased to announce the Decision to Grant on the European IRF7 Inhibitors case by the European Patent Office (EPO).
The patent application, EP3277813, relates to IRF7 inhibitors for use in treating bacterial infections. IRF7 inhibitors are a new way of regulating inflammation and resistance to infection. The European Patent Office (EPO) has granted the patent application as of September 16th, 2020 for 38 European countries.
Specific genes regulate innate immune responses to bacterial infection and the outcome of genetic variation can be beneficial or destructive, depending on the extent of inflammation and the efficiency of the anti-bacterial defense. Modulation of the innate immune system represents a promising, relatively under-explored alternative to failing antimicrobial therapies. It is essential to boost protective functions of host innate immunity, so that symptoms and tissue destruction caused by exaggerated host responses can be isolated and avoided.
The next steps for SelectImmune will be to complete the grant process by validating the granted European patent for the desired states.
“We have developed a new therapeutic approach to target the destructive response to infection in mice and improving bacterial clearance, and we are indeed pleased to see the patent application granted’’ says Catharina Svanborg.
This is an important step forward, broadening the SelectImmune patent portfolio with a new concept which has several potential applications”, says Ann Gidner.
For more information, please contact
Executive Chairman of the board, SelectImmune Pharma AB
+46-709 42 65 49
CEO, SelectImmune Pharma AB
+46 768 17 14 14
SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company’s goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.